

Dynamics of the Anti-factor VIII Antibody Signature During Treatment With Emicizumab

NCT05802836

Status RECRUITING
Sponsor Christoph Königs
Enrollment 100 participants

Key Eligibility Criteria

Inclusion (3)

- Severe congenital hemophilia A (CHA)
- Treatment with emicizumab irrespective of any other treatment
- Informed consent

Exclusion (3)

- No therapy with emicizumab
- Immunosuppressive therapy
- HIV-infection with CD4 (cluster of differentiation 4) cells $<200/\mu\text{l}$

Locations (1 total)

University Hospital Frankfurt, Goethe University, Frankfurt am Main, Hesse, Germany